ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2327

14-3-3η (eta) Protein in Juvenile Idiopathic Arthritis (JIA) Patients

Austin M. Dalrymple1, Paul Tuttle IV1, Lance Feller2, Olga S. Zhukov3, Robert J. Lagier4, Robert Bridgforth5, Gary J Williams5, Joanna M. Popov3, Stanley J. Naides3 and Terry Moore6, 1Division of Adult & Pediatric Rheumatology, Saint Louis University School of Medicine, Saint Louis, MO, 2Rheumatology, Inland Hospital, Waterville, ME, 3Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, 4Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, 5Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, 6Division of Adult & Pediatric Rheumatology, Saint Louis University School of Medicine, St. Louis, MO

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biomarkers and juvenile idiopathic arthritis (JIA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Pediatric Rheumatology – Pathogenesis and Genetics Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: 14-3-3 proteins are chaperonins found in all eukaryotic cells. There are multiple isoforms which are thought to be involved in intracellular signaling and transcription regulation. Recent work has implicated the η (eta) isoform as having diagnostic potential in inflammatory arthritides. Its utility in JIA has not been established. Our preliminary prior investigation indicated positivity in some JIA patients. In this study, we investigated a much larger cohort of patients with JIA and disease and healthy controls.

Methods: Measurement of 14-3-3η protein was evaluated in 29 rheumatoid factor (RF) positive (pos) polyarticular (poly) JIA patients, 29 RF negative (neg) poly patients, 34 oligoarticular (oligo) patients, 12 systemic-onset (SO) patients, 19 adult rheumatoid arthritis (RA) patients, 60 patients with systemic lupus (SLE), and 20 healthy controls by the assay established at Quest Diagnostics. Comparisons were made to CBC, ESR, CRP, RF and anti-CCP isotypes, and ANA positivity.

Results: 14-3-3η at 0.2 ng/ml or higher was considered positive; values of 0.5 ng/mL or greater have been considered prognostic of poor outcome in adults. Ten of 29 (34%) RF pos polys were positive for the 14-3-3η protein; 8 (28%) had values > 0.5 ng/mL. Nine of 29 (31%) RF neg polys were positive; 8/29 (28%) had values >0.5 ng/mL. Only 6/34 (18%) oligos were positive; 5/34 (15%) >0.5 ng/mL. Only 2/12 (16%) SO were positive; 1/12 (8%) >0.5 ng/mL. In the disease controls, 14/60 (23%) SLE were positive, but only 7/60 (12%) >0.5 ng/mL. 7/19 (37%) RA patients were positive, 4/19 (21%) >0.5 ng/mL. In the healthy controls, only 3/20 (15%) were positive, 1/20 (5%) > 0.5 ng/mL. The RF pos and RF neg polys positivity, especially at values >0.5 ng/mL compared favorably with the adult RA patient and were notable compared to disease and healthy controls. A weak correlation was noted between 14-3-3η positivity and CRP. Five of the 8 RF neg polys at original diagnosis that were 14-3-3η positive at >0.5 ng/mL have subsequently developed a positive RF and an anti-CCP antibody isotype. Also, the one SO positive for 14-3-3η >0.5 ng/mL also developed a positive RF.

Conclusion: Significant levels of 14-3-3η protein can be found in about 30% of RF pos and RF neg poly JIA patients. It may represent a new biomarker for RF neg poly JIA patients and a marker indicating the possibility of these patients becoming RF/anti-CCP antibody positive in the future. Further longitudinal studies are required to confirm these findings.


Disclosure: A. M. Dalrymple, None; P. Tuttle IV, None; L. Feller, None; O. S. Zhukov, Quest Diagnostics, 3; R. J. Lagier, Quest Diagnostics, 1,Quest Diagnostics, 3; R. Bridgforth, Quest Diagnostics, 3; G. J. Williams, Quest Diagnostics, 1,Quest Diagnostics, 3; J. M. Popov, Quest Diagnostics, 1,Quest Diagnostics, 3; S. J. Naides, Quest Diagnostics, 3,Quest Diagnostics, 1; T. Moore, None.

To cite this abstract in AMA style:

Dalrymple AM, Tuttle P IV, Feller L, Zhukov OS, Lagier RJ, Bridgforth R, Williams GJ, Popov JM, Naides SJ, Moore T. 14-3-3η (eta) Protein in Juvenile Idiopathic Arthritis (JIA) Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/14-3-3%ce%b7-eta-protein-in-juvenile-idiopathic-arthritis-jia-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/14-3-3%ce%b7-eta-protein-in-juvenile-idiopathic-arthritis-jia-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology